BullFrog AI Secures $3.13 Million in Funding Through Registered Direct Offering and Private Placement

BullFrog AI Raises $3.13 Million in Strategic Funding Round

BullFrog AI Holdings, Inc. (NASDAQ: BFRG), a technology-enabled drug development company leveraging artificial intelligence (AI) and machine learning, has successfully closed a significant funding round, raising approximately $3.13 million in gross proceeds 1

1

2

2

3

3

. This financial boost comes at a crucial time for the company as it seeks to advance its AI-driven pharmaceutical development platform.

Offering Structure and Details

The funding was secured through a combination of a registered direct offering and a concurrent private placement 1

1

2

2

. The specifics of the deal include:

• Issuance of 1,565,000 shares of common stock (or common stock equivalents)
• Concurrent private placement of common warrants to purchase up to 1,565,000 shares
• Combined purchase price of $2.00 per share and associated warrant
• Warrants have an exercise price of $2.00 per share
• Warrants are exercisable six months from issuance and expire five years from the initial exercise date 1

  1

  3

  3

Strategic Implications for BullFrog AI

This influx of capital is expected to bolster BullFrog AI's position in the competitive landscape of AI-driven drug development. The company's proprietary bfLEAP™ artificial intelligence platform is designed to analyze complex biological, clinical, and real-world data networks across various stages of drug development 4

4

. By leveraging this technology, BullFrog AI aims to:

1. Streamline data analytics in therapeutics development
2. Decrease overall development costs by reducing failure rates for new therapeutics
3. Enhance the efficiency of early discovery to late-stage clinical trials 4

   4

Market Context and Industry Impact

The successful funding round for BullFrog AI reflects a broader trend of increasing investment in AI-powered healthcare and pharmaceutical technologies. As the industry continues to recognize the potential of AI in drug discovery and development, companies like BullFrog AI are positioned to play a crucial role in shaping the future of medicine.

Financial and Legal Considerations

WallachBeth Capital, LLC acted as the sole placement agent for both the registered direct offering and private placement 1

1

2

2

. The offering was conducted under an effective shelf registration statement, ensuring compliance with SEC regulations. However, the common warrants and their underlying shares were offered through a private placement exemption under Section 4(a)(2) of the Securities Act 1

1

3

3

.

Looking Ahead

While this funding round marks a significant milestone for BullFrog AI, the company faces the ongoing challenges of a highly competitive and rapidly evolving industry. The success of its AI platform in delivering tangible results in drug development will be crucial for maintaining investor confidence and securing future growth opportunities.

As with any forward-looking statements in the biotech and AI sectors, investors are cautioned that actual results may differ from projections due to various risks and uncertainties inherent in the industry 1

1

3

3

4

4

.